Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis.
checkpoint inhibitor
dendritic cell vaccination
glioblastoma
immunotherapy
survival
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
04 02 2022
04 02 2022
Historique:
received:
06
12
2021
revised:
26
01
2022
accepted:
01
02
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
3
2022
Statut:
epublish
Résumé
Dendritic cell vaccination (DCV) strategies, thanks to a complex immune response, may flare tumor regression and improve patients' long-term survival. This meta-analysis aims to assess the efficacy of DCV for newly diagnosed glioblastoma patients in clinical trials. The study databases, including PubMed, Web of Knowledge, Google Scholar, Scopus, and Cochrane, were searched by two blinded investigators considering eligible studies based on the following keywords: "glioblastoma multiforme", "dendritic cell", "vaccination", "immunotherapy", "immune system", "immune response", "chemotherapy", "recurrence", and "temozolomide". Among the 157 screened, only 15 articles were eligible for the final analysis. Regimens including DCV showed no effect on 6-month progression-free survival (PFS, HR = 1.385, 95% CI: 0.822-2.335, Antitumor regimens including DCV can effectively improve mid-term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in patients affected by a very poor prognosis.
Sections du résumé
BACKGROUND
Dendritic cell vaccination (DCV) strategies, thanks to a complex immune response, may flare tumor regression and improve patients' long-term survival. This meta-analysis aims to assess the efficacy of DCV for newly diagnosed glioblastoma patients in clinical trials.
METHODS
The study databases, including PubMed, Web of Knowledge, Google Scholar, Scopus, and Cochrane, were searched by two blinded investigators considering eligible studies based on the following keywords: "glioblastoma multiforme", "dendritic cell", "vaccination", "immunotherapy", "immune system", "immune response", "chemotherapy", "recurrence", and "temozolomide". Among the 157 screened, only 15 articles were eligible for the final analysis.
RESULTS
Regimens including DCV showed no effect on 6-month progression-free survival (PFS, HR = 1.385, 95% CI: 0.822-2.335,
CONCLUSION
Antitumor regimens including DCV can effectively improve mid-term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in patients affected by a very poor prognosis.
Identifiants
pubmed: 35200574
pii: curroncol29020075
doi: 10.3390/curroncol29020075
pmc: PMC8870360
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
881-891Références
Expert Opin Biol Ther. 2015 Jan;15(1):79-94
pubmed: 25327832
Cancer Immunol Immunother. 2018 Nov;67(11):1777-1788
pubmed: 30159779
PLoS One. 2014 Sep 12;9(9):e107173
pubmed: 25215607
J Clin Neurosci. 2011 Aug;18(8):1048-54
pubmed: 21715171
Adv Immunol. 1994;57:281-351
pubmed: 7872159
Klin Onkol. 2019 Winter;32(1):70-74
pubmed: 30764633
Clin Cancer Res. 2005 Jun 1;11(11):4160-7
pubmed: 15930352
Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45
pubmed: 27223671
Cancer Immunol Immunother. 2013 Sep;62(9):1499-509
pubmed: 23817721
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Cancer Gene Ther. 2020 Aug;27(7-8):558-570
pubmed: 30464207
Cancer J. 2016 Mar-Apr;22(2):73-80
pubmed: 27111901
Nat Rev Clin Oncol. 2019 Jul;16(7):425-441
pubmed: 30914826
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Cancer Res. 2004 Jul 15;64(14):4973-9
pubmed: 15256471
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
J Immunoassay Immunochem. 2019;40(1):70-80
pubmed: 30497337
Clin Cancer Res. 2011 Mar 15;17(6):1603-15
pubmed: 21135147
Sci Rep. 2018 Aug 7;8(1):11800
pubmed: 30087385
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Clin Cancer Res. 2019 Oct 1;25(19):5799-5807
pubmed: 31320597
BMC Neurol. 2020 Oct 21;20(1):382
pubmed: 33087049
Br J Cancer. 2003 Oct 6;89(7):1172-9
pubmed: 14520441
World Neurosurg. 2012 May-Jun;77(5-6):736-44
pubmed: 22120301
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Front Immunol. 2021 Mar 09;11:603911
pubmed: 33767690
Prostate. 1996 Jan;28(1):65-9
pubmed: 8545283
Haematologica. 2014 Oct;99(10):1538-46
pubmed: 25271313
Nature. 2015 Mar 19;519(7543):366-9
pubmed: 25762141
EBioMedicine. 2020 Oct;60:102987
pubmed: 32942121
Comput Math Methods Med. 2017;2017:5291823
pubmed: 28912828
Cell Biochem Biophys. 2012 Jan;62(1):91-9
pubmed: 21909820
J Immunol. 1997 Jul 15;159(2):770-6
pubmed: 9218594
Cancers (Basel). 2018 Oct 05;10(10):
pubmed: 30301187
Cancers (Basel). 2019 Apr 11;11(4):
pubmed: 30979057
Nature. 1997 Jun 12;387(6634):713-7
pubmed: 9192897
Bull Exp Biol Med. 2007 Apr;143(4):528-34
pubmed: 18214316
Neuro Oncol. 2014 Nov;16(11):1441-58
pubmed: 25190673
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Clin Cancer Res. 2017 Apr 15;23(8):1898-1909
pubmed: 28411277
Aust Fam Physician. 2017;46(4):194-199
pubmed: 28376571
Int J Clin Pharmacol Ther. 2014 Jan;52(1):76-7
pubmed: 24321210
Nature. 1995 May 11;375(6527):151-5
pubmed: 7753172
J Neurooncol. 2015 Sep;124(2):325-32
pubmed: 26070556
Clin Cancer Res. 2004 Aug 15;10(16):5316-26
pubmed: 15328167
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
Expert Rev Vaccines. 2017 Jan;16(1):27-36
pubmed: 27500911